Return to homepagePandemic Pact

Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93022C00034-0-9999-1

Grant search

Key facts

  • Disease

    West Nile Virus Infection

  • Start & end year

    2022
    2025

  • Known Financial Commitments (USD)

    $2,997,218

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    DAVID CLEMENTS

  • Research Location

    United States of America

  • Lead Research Institution

    HAWAII BIOTECH, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The contract supports the development of TLR4 agonist within an oil-in-water emulsion as a vaccine adjuvant. The adjuvant development activities are being conducted within the context of vaccines to protect against West Nile virus infection.